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 1 
Introduction 
 
Rabies is caused by a group of related viruses, Lyssaviruses, of which there are now 14 
recognized species (International Committee on Taxonomy of Viruses, ICTV). Among the 
Lyssavirus species, Rabies Virus, the one with the greatest public health impact, is further 
divided into numerous virus variants which are maintained in specific reservoir populations. The 
canine rabies virus variant, responsible for dog-to-dog transmission of rabies, is a threat to 
human health and responsible for an estimated 59,000 deaths each year (Hampson et al 2015). In 
many regions including most of North America and Europe, the canine rabies virus variant was 
pushed to extinction through mandatory dog vaccination and stray dog control (WHO Expert 
Consultation on Rabies, 2013).  
 
Although preventative control measures have minimized the incidence of canine rabies in 
developed countries, recommendations on rabies vaccination for domestic dogs vary among 
countries and even within states and provinces. The National Association of State Public Health 
Veterinarians recommends that regardless of the age of the animal at initial vaccination, a 
booster vaccination should be administered one year later.  All licensed rabies vaccine 
manufacturers have approved an initial vaccination can occur as early as three months of age 
(Rabies Compendium 2016). However, state and local governments regulate the administration 
of rabies vaccinations whereby the age at initial vaccination and required frequency can vary 
(AVMA Sate Laws 2016).  Most states require administration of the initial vaccine by 3-4 
months of age and subsequent booster vaccination annually or every 3 years; however, there is 
no epidemiologic or laboratory data available to support the annual or biennial administration of 
3- or 4-year vaccines after the initial series (Rabies Compendium 2016).  
 
Vaccination against rabies is not assumed to be 100% protective. Rabies neutralizing antibody 
titers ≥ 0.5 IU/mL has been defined by the WHO and OIE as the minimum post vaccination 
antibody level (OIE 2011, WHO 2013). However, neutralizing antibodies levels decline over 
time in vaccinated animals and are dependent on the timing of the blood sampling for antibody 
measurement in relation to vaccination. Therefore, if the timing of antibody measurement is 
delayed months or even years after vaccination, the level of circulating antibody may not be 
 2 
detectable. This does not mean that the animal did not have an adequate response immediately 
post-vaccination and it does not mean that the animal is susceptible to rabies challenge (Aubert 
1993, Moore and Hanlon 2010). While the majority of animals tend to achieve the recommended 
titer threshold 7-14 days post-vaccination (Sage et al., 1993; Sihoven et al., 1995; Cliquet et al., 
2003; Mansfield et al., 2004; Kennedy et al.; 2008), some animals may fail to mount an 
immunological response to rabies vaccination and therefore protection against rabies challenge 
cannot be conferred from a history of vaccination alone.  
 
Countries that have eliminated the canine rabies virus variant often require proof of vaccination 
and/or proof of adequate rabies antibody titer for pet import. For example, dogs importing to 
New Zealand, a rabies free country, are required to have received a rabies vaccine given no less 
than six months and not more than one year prior to the date of shipment. In addition, a proof of 
a rabies antibody test with a result of at least 0.5 IU/ml is required whereby the blood sample 
was collected not less than three months and not more than 24 months prior to the date of entry. 
Depending on the jurisdiction, dogs without proof of vaccination may be, turned away, 
euthanized, or in special occasions granted access through special monitoring programs (USDA, 
Pet Travel 2016).  
 
For many canine rabies-free countries, imported dogs must have documentation of a rabies 
antibody titer value of ≥ 0.5 IU/ml for entry. However, multiple factors likely play a role in 
whether of not an animal is likely to achieve this value, including biological factors, vaccination 
schedules, and the timing of the blood draw for the antibody test.  The purpose of this study is to 
assess the risk factors that may contribute to the failure of an animal to respond adequately after 
primary rabies vaccination.  
 
Materials and Methods 
 
Serum samples with accompanying dog-demographic data from 162,739 animals were submitted 
to the Kansas State University Rabies Laboratory between 2006 and 2010 for the detection of 
rabies antibody titer levels for the purpose of pet travel. Samples were tested via Fluorescent 
Antibody Virus Neutralization (FAVN) testing and data from submission forms were entered 
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into Microsoft Access and the Universal Veterinary Information System.  Submission forms 
included the name and address of the submitting clinic or laboratory and the animal’s 
information (species, name, identification number, birthdate, sex, breed, vaccination history, and 
serum draw date).   
 
This study was conducted to evaluate the detection of rabies antibody in naïve dogs after primary 
vaccination. Therefore, the dataset was further limited to dogs under one year of age (n = 13,061) 
and with no documented history of prior rabies vaccination (n = 8,571). Sample data associated 
with submission forms without an identification number, birth date, serum draw date, and 
vaccination history were omitted from the study.  
 
All qualifying dogs were categorized into early vaccination (<12 weeks), on-time vaccination 
(12-16 weeks), and late vaccination (>16 weeks). Data from a subset of dogs (10%) from each 
category were compared to their original submission form for accuracy of dataset information. 
Systematic errors were found in a small subset of dogs, which has shorter intervals between 
vaccination blood draws and biologically implausible rabies titer values.  These observations 
were assessed for errors primarily associated with erroneous dates. Failure to record accurate 
information either on the original submission or upon transfer into the database was identified to 
the source of error regarding a higher than expected titer result for these observations. Correction 
of all records in the dataset with the appropriate information on the submission form was 
completed, and the records remained in the dataset for analysis. Records that could not be 
verified and corrected were assumed to be biologically implausible and removed from the 
dataset. The total eligible sample size was 8,367 dogs.  
 
The sera were analyzed using the Fluorescent Antibody Virus Neutralization (FAVN) test 
(Cliquet et al 1998). Sera with a titer less than 0.5 IU/ml were considered to have a failed test 
and a titer greater than or equal to 0.5 IU/ml was considered to have a passing test (WHO). 
Canine samples were categorized into the following cut-off titer groups: 0 - <0.5 IU/ml (Low 
responders), ≥0.5 - <1.5 IU/ml (Moderate responders), ≥1.5 - 2.62 IU/m (High responders). The 
categories were chosen to further delineate the failed and passing groups.  
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Canine samples less than 1 year of age at the time of vaccination were categorized into three age 
groups: less than 12 weeks of age, 12-16 weeks of age, and greater than 16 weeks of age. 
Recommendations from the National Association of State Public Health Veterinarians 
(NASPHV) state a one-year killed rabies vaccination should be administered not earlier than 12 
weeks of age with revaccinations one year following the initial vaccinations (Compendium of 
Animal Rabies Prevention and Control, 2016). Therefore all canine samples with an initial 
vaccination prior to 12 weeks were grouped and considered early vaccinations. Most state 
regulations require that a dog be vaccinated prior to 16 weeks of age, therefore, defining the 
second age category and considered on schedule. Dogs receiving rabies vaccination later than 16 
weeks were considered late immunizations.  
 
The time of initial vaccination to sample draw date was calculated based on dates provided on 
submission forms and defined as the draw-delay period.  Eight draw-delay periods were defined 
as follows: 1) ≤ 3 days, 2) 4 days to ≤ 7 days, 3) 8 days to ≤ 15 days, 4) 16 days to ≤ 35 days, 5) 
36 days to ≤ 77 days, 6) 78 days to ≤ 154 days, 7) 155 days to ≤ 224 days, and 8) > 224 days.  
 
The submission form accompanying the sample included an entry titled breed.  If the breed of 
the animal was known then that breed was entered in the space provided. If the breed was 
unknown then “mixed” was entered into the space provided. If the animal was designated a breed 
and mixed then the animal was entered into the database as the primary breed of the animal. The 
analysis did not delineate between different breeds but rather assessed the variables of pure breed 
verse mixed breed.  
 
Breed was used to categorize dogs into 5 size groups: toy, small, medium, large, and giant. The 
American Kennel Club (AKC) has defined each size group with a weight range and the breeds 
included in each size group. The AKC groupings were used to define the size groups in this 
study.  
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Statistical Analysis 
 
Statistical analyses were performed with SAS software. Comparison of the frequency for these 
variables was analyzed using the Cochran-Mantel-Haensel test of significance. Geometric mean 
titers were calculated by different groups mentioned previously and Analysis of Variance 
(ANOVA) was used to determine if these means significantly differed. Serological responses 
were plotted by the delay in drawing the blood to check the titer (draw-delay) and viewed in two 
ways; proportions failing to reach 0.5 IU.ml and GMT (Figure 1 and 2). A polynomial trend line 
with 3 orders was determined to provide the best fit for the data.   
Results 
 
The number of dog samples less than 1 year of age with no documented history of prior 
vaccinations before the vaccination given to qualify for pet travel was 8,571. A total of 204 
(2.4%) dogs were removed from analysis due to missing or inconsistent data, for a final study 
sample size of 8,367 dogs (table 1). The number of dog samples that failed the FAVN test (<0.5 
IU/ml) included 1,002 (11.7%) samples and the number of dog samples that passed the FAVN 
test (>0.5 IU/ml) included 7,365 (85.9%) samples. A lower proportion of dogs failed when they 
were vaccinated at an age greater than 16 weeks compared to dogs vaccinated early or on-time 
(10.4% compared to 16.3% and 15.5%) (Table 1) 
 
The geometric mean titer (GMT) for all dogs sampled was 1.49 IU/mL (Table 2) with a standard 
deviation of 1.49. 
Further delineation of the sample numbers into three age groups at which the primary 
vaccination was received is displayed in Table 2. The influence of age on antibody titer response 
was significant for all three age groups with dogs vaccinated age greater than 16 weeks having 
the highest GMT (1.6 IU/ml) (Table 2). There is no statistical difference in GMT between dog 
vaccinated early and dogs vaccinated on-time (1.27 IU/ml compared to 1.27 IU/ml) (Table 2).  
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Table 1: Rabies Vaccination Data- Dogs less than 1 year of age given only 1 Rabies vaccine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Percentage out of <12 weeks group (301) 
*Percentage out of 12-16 weeks group (2,291) 
***Percentage out of >16 weeks group (5,77 
 
 
 
Table 2: Number of dog samples by titer range and age at primary vaccination 
 
 Rabies Serological Titer Range of Values  
Age at 
Primary 
Vaccination 
0-<0.5 
 
0.5-≤02.6 
 
>2.62 Total CMH GMT Lower 
Limit 
Upper 
Limit 
ANOVA 
< 12 weeks 40 (3.9%) 124 (3.3%) 128 (3.4%) 301 
(3.5%) 
 1.27 1.08 1.49  
12-16 weeks 355 (35.4%) 1,081 (29.5%) 855 (23%) 2,291 
(27.3%) 
 1.27 1.20 1.34  
>16 weeks 598 (59.6%) 2,453 (67%) 2,724 
(73.4%) 
5,775 
(69%) 
 
 1.60 1.55 1.66  
Total 1,002 3,658 3,707 8,367 
(100%) 
<0.01 1.49   <0.01 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Samples % 
   
Total Dogs < 1 year 13,061  
Total Dogs < 1 year & 1 vaccine 8,571 65.6% 
Total plausible < 1 year & 1 vaccine 8,367 97.6% 
Geometric Mean Titer Value 1.33 IU/ml  
Total Dogs Failed to Reach 0.5 IU/ml 1,002 11.7% 
Total Dogs Reached or Surpasses 0.5 IU/ml 7,365 85.9% 
Age at Primary Vaccination < 12 weeks 301 3.6% 
Passed 252 83.7%* 
Failed 49 16.3%* 
Age at Primary Vaccination 12-16 weeks 2,291 17.5% 
Passed 1,936 84.5%** 
Failed 355 15.4%** 
Age at Primary Vaccination > 16 weeks 5,775 44.2% 
Passed 5,177 89.6%*** 
Failed 598 10.3%*** 
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Table 3:  Dogs Less than 12 Weeks of Age 
 RABIES ANTIBODY TITER VALUES  
  LOW 
RESPONDERS 
MODERATE 
RESPONDERS 
HIGH 
RESPONDERS 
CMH Geometric Mean 
Titer 
LN ANOVA 
A
g
e
 a
t 
v
a
cc
in
a
ti
o
n
: <
1
2
 W
e
e
k
s 
TOTAL 49 (16.3%) 124 (41.1%) 128 (42.5%)  1.27  
Sex a 0.51  0.93 
Male 25 (15.9%) 77 (42.6%) 65 (41.4%)  1.26  
Female 24 (17.2%) 56 (40.2%) 59 (42.45%)  1.25  
Unspecified 0 1 (20%) 4 (80%)  1.72  
Time from Vaccine Administration to Titer Check  <0.01  <0.01 
< 3 days 0 0 0  0  
4 to < 7 days 1 (25%) 1 (25%) 2 (50%)  1.32  
8 to < 15 days 0 0 4 (100%)  3.45  
16 to < 35 days 5 (6.1%) 29 (35.8%) 47 (58%)  1.99  
36 to < 77 days 15(21.1%) 26 (36.6%) 30 (42.2%)  1.15  
78 to < 154 days 19 (25%) 37 (48.6%) 20 (26.3%)  0.77  
155 to < 224 days 5 (15.6%) 14 (43.8%) 13 (40.6%)  1.18  
> 225 days 4 (12.1%) 17 (51.5) 12 (36.3%)  1.49  
Type of Dog 0.39  0.95 
Mixed Breed 10 (20.4%) 17 (34.6%) 22 (44.9%)  1.27  
Pure Breed 32 (14.4%) 97 (44.2%) 90 (41.1%)  1.29  
Dog Size    0.77  0.46 
Toy 4 (8%) 25 (50%) 21 (42%)  1.73  
Small 9 (15.8%) 23 (40.4%) 25 (43.9%)  1.41  
Medium 7 (18.4%) 15 (29.5%) 16 (42.1%)  1.18  
Large 11 (16.9%) 30 (46.2%) 24 (36.9%)  1.10  
Giant 1 (14.3%) 3 (42.9%) 3 (42.9%)  0.83  
Unspecified 17 (20.2%) 28 (33.3%) 39 (46.4%)  1.13  
 
 
 
 
Table 4: Dogs 12-16 Weeks of Age 
 RABIES ANTIBODY TITER VALUES  
  LOW 
RESPONDERS 
MODERATE 
RESPONDERS 
HIGH 
RESPONDERS 
CMH Geometric Mean 
Titer 
LN ANOVA 
A
g
e
 a
t 
v
a
cc
in
a
ti
o
n
: 1
2
-1
6
 W
e
e
k
s 
TOTAL 355 (15.4%) 1,081 (47.1%) 855 (37.3%)  1.27  
Sex 0.10  0.25 
Male 189 (16.7%) 530 (47%) 408 (36.2%)  1.23  
Female 164 (14.2%) 542 (47%) 445 (38.6%)  1.30  
Unspecified 2 (15.3%) 9 (69.2%) 2 (15.3%)  0.68  
Time from Vaccine Administration to Titer Check <0.01  <0.01 
< 3 days 7 (100%) 0  0  0.02  
4 to < 7 days 1 (25%) 1 (25%) 2 (50%)  0.43  
8 to < 15 days 5 (8.4%) 27 (45.7%) 27 (45. 7%)  1.52  
16 to < 35 days 46 (5.5%) 380 (45.4%) 410 (49.0%)  1.93  
36 to < 77 days 65 (12.9%) 248 (49.3%) 190 (37.7%)  1.35  
78 to < 154 days 124 (23.7%) 259 (49.5%) 140 (26.7%)  0.66  
155 to < 224 days 65 (27.9%) 113 (48.5%) 55 (23.6%)  0.65  
> 225 days 42 (33.3%) 53 (42%) 31 (24.6%)  0.69  
Type of Dog 0.19  0.34 
Mixed Breed 34 (13.3%) 133 (52.1%) 88 (34.5%)  1.35  
Pure Breed 298 (16.2%) 853 (46.3%) 688 (37.4%)  1.24  
 Dog Size    <0.01  <0.01 
Toy 52 (12.2%) 199 (46.7%) 175 (41.1%)  1.47  
Small 74 (14.6%) 236 (46.5%) 198 (39%)  1.37  
Medium 44 (16.7%) 118 (44.9%) 101 (38.4%)  1.25  
Large 112 (21%) 247 (46.3%) 175 (32.8%)  1.02  
Giant 11 (11.5%) 49 (51%) 36 (37.5%)  1.44  
Unspecified 62 (13.4%) 232 (50%) 170 (36.6%  1.25  
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Table 5:  Dogs Greater Than 16 Weeks of Age 
 RABIES ANTIBODY TITER VALUES  
  LOW 
RESPONDERS 
MODERATE 
RESPONDERS 
HIGH 
RESPONDERS 
CMH Geometric Mean 
Titer 
LN ANOVA 
A
g
e
 a
t 
v
a
cc
in
a
ti
o
n
: >
1
6
 W
e
e
k
s 
TOTAL 598 (10.3%) 2,453 (42.4%) 2,724 (47.1%)  1.60  
Sex 0.47  0.44 
Male 291 (9.8%) 1263 (42.9%) 1386 (47.1%)  1.62  
Female 301 (10.8%) 1161 (41.7%) 1316 (46.3%)  1.58  
Unspecified 6 (8.9%) 29 (51.7%) 22 (39.2%)  1.34  
Time from Vaccine Administration to Titer Check  <0.01  <0.01 
< 3 days 40 (100%) 0 0  0.05  
4 to < 7 days 11 (8.5%) 35 (37.2%) 51 (54.2%)  1.65  
8 to < 15 days 19 (5.25%) 116 (32.%) 227 (62.7%)  2.22  
16 to < 35 days 66 (2.9%) 826 (36.8%) 1351 (60.2%)  2.30  
36 to < 77 days 119 (8.5%) 655 (47%) 618 (44.4%)  1.63  
78 to < 154 days 214 (19.7%) 544 (50.2%) 324 (29.9%)  1.04  
155 to < 224 days 113 (23.2%) 240 (49.4%) 132 (27.2%)  0.84  
> 225 days 19 (24.6%) 37 (48%) 21 (27.2%)  0.76  
Type of Dog <0.01  <0.01 
Mixed Breed 66 (8%) 343 (41.8%) 410 (50%)  1.77  
Pure Breed 498 (10.8%) 1944 (42.4%) 2138 (46.6%)  1.57  
Dog Size    <0.01  <0.01 
Toy 124 (9.2%) 563 (41.7%) 664 (49.1%)  1.67  
Small 142 (10.6%) 577 (43.1%) 620 (46.3%)  1.60  
Medium 56 (10%) 241 (43.2%) 261 (46.8%)  1.71  
Large 144 (12.9%) 480 (42.9%) 495 (44.2%)  1.42  
Giant 29 (14.9%) 74 (37.9%) 92 (47.2%)  1.44  
Unspecified 102 (8.4%) 518 (42.7%) 592 (48.8%)  1.61  
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Among dogs vaccinated yearly, sex and breed-type had no statistically significant influence on 
the measured antibody response (CMH p=0.51 and 0.39, ANOVA p=0.93 and 0.95).  The 
influence of the draw-delay period on titer response was statistically significant (CMH, ANOVA 
p= <0.01). The time between vaccination and blood draw was significantly associated with titer 
value, with the highest GMT seen between days 8-35 (3.45 and 1.99 IU/ml). A greater proportion 
of dogs were classified as “high responder” when their titer was checked 8-77 days after 
vaccination.  
 
Among dogs vaccinated on-schedule, sex and breed did not influence their antibody response 
(CMH p=0.1, 0.19, ANOVA p=0.25, 0.34).  Dog size did influence antibody response 
(CMH, ANOVA p<0.01) and large breed dogs had the highest failure rate (21%) and lowest 
GMT (1.02). The influence of the draw-delay period on titer response was statistically significant 
(CMH, ANOVA p= <0.01). The overall GMT was 1.27 and 15.4% of dogs failed.  Failure rates 
were higher when titers were checked within 7 days and after 78 days of vaccination. The highest 
GMT occurred when titers were checked 4-35 days post-vaccination. After day 36-post 
vaccination an inverse relationship between was observed between titer response and delay in 
titer check with titer response decreasing as the delay period increased.  
 
Dogs vaccinated after 16 weeks of age has no significant association between rabies antibody titer 
and the dog’s sex (CMH p=0.47, ANOVA p=0.44). The influence of breed on antibody response 
was statistically significant both in terms of titer group and GMT (CMH, ANOVA p= <0.01), 
mixed breed dogs had a higher GMT (1.77 vs 1.57) and lower failure rate (8.0% vs 10.8%) 
compared to pure breed dogs. The influence of size on antibody response was statistically 
significant for both titer group and GMT (CMH, ANOVA p= <0.01), toy, small and medium dogs 
had a higher GMT than large and giant dogs. The influence of the draw-delay period on titer 
response is was statistically significant (CMH, ANOVA p<0.01). The highest GMT was observed 
when titers were drawn between days 4-36 days post vaccination. After day 36-post vaccination 
there was an inverse relationship between titer response and the draw-delay period with titer 
response decreasing as the draw-delay period increasing The highest rate of failure is at day 3 or 
less and greater than 78 days.  The failure rate was higher when the titer was checked 78 days or 
greater after vaccination. The failure rate was 8 times higher among dogs that had a titer draw-
delay of 225 days or greater compared to dogs sampled at 16-35 days post-vaccination.  
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When serological data were plotted by the delay between vaccination and titer draw, all 
vaccination age groups showed a polynomial relationship (Figure 1). Rates of failure were highest 
when titers were drawn shortly after vaccination with the failure rate dropping below 20% when 
titers were drawn approximately 10 days after vaccination. According to the polynomial trend 
lines, failure rates were relatively low when titer was checked between 12 and 27 days post 
vaccination. Failure rates rose when titers were checked approximately 25 days post-vaccination. 
A similar relationship was noted among GMTs, with titers low within the first five days post-
vaccination, raising to their peaks 15 days post-vaccination, and declining steadily after (Figure 
2). Dogs vaccinated on time and late have higher-squared values (0.4, 0.79). Model fit was poor 
for dogs vaccinated early (r-square = 0.04 and 0.1).  
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Figure 1: Proportion of dogs failing the antibody titer test 
 
 
Figure 2: Geometric Mean Titer 
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Discussion 
 
This study conducted the largest retrospective review of rabies vaccine naïve dog’s response to 
primary vaccination.  Dogs vaccinated later than 16 weeks of age had a higher GMT; however, early 
vaccination was not associated with a higher rate of failure nor was it associated with lower GMT 
when compared to dogs vaccinated on time. Some demographic factors may influence serological 
responses to vaccination such as breed-type and dogs size but their influence appears minimal and 
needs further, targeted exploration. In this study, the greatest risk for a dog failing to achieve an 
adequate immune response to rabies vaccination was associated with the timing of the blood draw 
following vaccination.  Sample collection occurring too early or too late resulted in a higher failure 
rate.  
 
In today’s globalized world, people and their pets can now traverse continents in a matter of hours. 
While this progress has eased international trade and communications, a pathway for infectious 
diseases to travel rapidly across vast distances has emerged. Countries that have undergone the 
financial and physical responsibility to eliminate canine rabies virus have a high priority when it 
comes to protecting that status. Most canine rabies-free countries require evidence of vaccination 
for the purpose of pet travel.  Serological testing for rabies antibodies is intended to validate that an 
animal has achieved an appropriate immunologic response following vaccination. If achieved, the 
animal is assumed to pose no rabies importation risk to the country.  While many rabies-free 
countries require proof of a titer test prior to entry, each individual country may have additional 
time sensitive deadlines for time of vaccination and sample collection for testing. This study, 
consistent with literature from Tepsumethanon et al 1991, Sage et al 1993, Sihvonen et al 1995, 
Cliquet 2003, Mansfield et al 2004, Kennedy et al 2007, Jakel et al 2008, and Berndtsson et al 2011) 
showed a high risk of failure to document serological conversion when titers were drawn prior to 
8-days and after 77 days from the time of vaccination. Failure to document serological conversion 
may result in added expense for the owner to repeat the test, additional vaccine booster doses for 
the dog, of the denial of entry of a pet into a country, or costly in-country quarantine. For pet 
owners, coordinating travel plans in alignment with meeting vaccination and titer requirement 
need to be well calculated to ensure successful entry into the importing country.  
 
Previous studies have shown that dogs less than 1 year of age have a higher risk of failure to 
achieve an adequate rabies titer after vaccination (Mansfield et al 2004, Kennedy et al 2007, 
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Berndtsson et al 2011, Seghaier et al 1999).  Two reasons likely explain this finding. First, dogs 
under one year of age are likely to be receiving their first rabies dose and a primary response is 
being measured.  The second reason is that older dogs potentially have two advantages; they have a 
more mature immune response compared to very young dogs (Day 2007), and they may have had 
more than one vaccine and are displaying an anamnestic response to vaccination (Seghaier et al., 
1999). This study exclusively looked at characteristics of dogs less than one year of age with a 
history of only one rabies vaccination to ensure that only factors associated with failure after 
primary vaccination was measured. Consistent with other studies, this analysis showed that 
vaccination at older age was associated with a significant decrease in probability of failure. This 
retrospective study was not designed to explain why older age was associated with higher GMT; 
however, it is likely due to the maturation of the functional immune system as animal’s age or the 
absence of maternal antibody interference. 
 
The World Health Organization (WHO) recently revised recommendations for canine rabies 
endemic countries to vaccinate dogs of any age that present to a mass vaccination clinic (WHO 
Expert Consultation). The decision was based primarily on the need to eliminate time wasted at 
vaccination clinics to verify animal age and to maximize the campaign’s ability to vaccinate a dog 
that would otherwise not be vaccinated. The results of this study indicate that vaccinating dogs at 
an earlier age (less than 12 weeks) is likely to be just as successful as vaccination of dogs at the ages 
recommended by nation and manufacturer recommendations. This study did not evaluate the effect 
of very early-age vaccination and age at vaccination was categorical, but the findings support the 
WHO stance on vaccination of all dogs presented to a mass vaccination campaign regardless of age.  
 
The association between dog breed or size and the probability of mounting an adequate serological 
response has also been evaluated by; Berndtsson 2011, Kennedy 2007, and Zanoni 2010. In these 
papers, large breed dogs appear to fail at a higher rate compared to small breed dogs. A similar 
association was found in this study with significant differences in failure rate and GMT between 
both breed type and dog size.  Various theories attempt to explain the effect of this variable, 
primarily breed-specific genetic traits and the delivered antigenic load in a vaccine dose.  The 
antigenic load is proportionally larger to a small breed dog and may stimulate a more robust 
response in the small and toy breeds.  This study is not able to further explain the effect of breed 
and size as the associations are not strong and possible attributable to a multitude of factors.  
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Studies designed to specifically address this relationship should be carried out to differentiate the 
roles of genetic factors, antigenic load, and likely other factors at play.  
 
The recent revisions in national guidelines for managing animals with potential rabies exposures 
recommend checking titers for animals with questionable vaccination history for evidence of an 
anamnestic response (significant rise in titer and a value of at least 0.5 IU/ml) (NASPHV 
Compendium of Animal Rabies Prevention and Control, 2016, Part I B.5(4b)). The recommendation 
is based on the theory that only animals with previous history of vaccination will show a robust 
immune response within seven days of a rabies booster vaccination. In this study, a large 
proportion of rabies vaccine-naïve dogs showed a robust immune response within only seven days; 
61% achieved a serological response above 0.5 IU/ml within only seven days. The high percentage 
of dogs in this study reaching 0.5 IU/ml RVNA level at day 7 could be attributed to the presence of 
maternal antibodies (especially at less than 12 weeks of age) (Day 2007) of undocumented 
previous vaccination (especially in dogs vaccinated at greater than 16 weeks of age). Evidence of a 
robust immune response to vaccination likely confers immunity against developing rabies; 
however, this can never be guaranteed. The findings from this study suggest that detection of an 
immune response at 0.5 IU/ml within seven days of rabies vaccination cannot be used to establish a 
history of vaccination.  
Limitations 
 
This retrospective study was conducted using a large dataset of information and was subject to 
error from two major sources; the recorded submission forms at the submitting clinics and data 
entry at the receiving laboratory.  Additional areas within this study that could lead to 
misinterpretation of the data include; distribution of data into variable categories, the handling of 
missing data, variance of laboratory methods, and a significance bias given the statistical tests 
chosen.  While the analysis performed was intended to be preliminary, repeating the analysis using 
a logistic regression would allow the strength of association to be better quantified.   
 
Conclusion  
 
This study provides additional findings that could potentially have implications for current and 
future guidelines as they pertain to pet travel, vaccination campaigns, and exposure 
recommendations. Furthermore, the study provides insight into additional research needed within 
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the area of rabies serology specifically as it pertains to the influence of breed or dog size, primary 
versus anamnestic responses to vaccination, and smaller sampling intervals to determine the initial 
detection of immunocompetence. 
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